17α-Hydroxyprogesterone Caproate Linked With Reduction in Early Births

Reduction in delivery at less than 24 weeks of gestation compared with cerclage alone
Reduction in delivery at less than 24 weeks of gestation compared with cerclage alone

HealthDay News — For women with a prior preterm birth, cerclage plus 17α-hydroxyprogesterone caproate is associated with a significant reduction in delivery at less than 24 weeks of gestation compared with cerclage alone, according to a study published in the November issue of Obstetrics & Gynecology.

Bethany Stetson, MD, from the Ohio State Wexner Medical Center in Columbus, and colleagues identified women with transvaginal cerclage placement and a prior delivery between 16 and 36 weeks of gestation over a 10-year period. Outcomes, including the primary outcome of delivery at less than 24 weeks of gestation, were compared for women with a cerclage alone (171 women) and those with cerclage plus 17α-hydroxyprogesterone caproate (89 women).

The researchers found that delivery at less than 24 weeks of gestation occurred in 6 and 16% of women receiving cerclage plus 17α-hydroxyprogesterone caproate and cerclage alone (odds ratio, 0.31). The combined treatment group had a 73% reduction in delivery compared with the cerclage-alone group after the researchers controlled for indomethacin use, prior cerclage, and loop electrosurgical excision procedure-cold knife cone and cerclage surgery (adjusted odds ratio, 0.26).

"Women receiving transvaginal cerclage plus 17α-hydroxyprogesterone caproate had a 69% relative reduction in delivery at less than 24 weeks of gestation when compared with women receiving cerclage alone," the authors write.

Full Text (subscription or payment may be required)

Loading links....